Efficacy and safety of tacrolimus in de novo pediatric transplant recipients randomized to receive immediate- or prolonged-release tacrolimus.
Karel VondrakFrancesco ParisiAnil DhawanRyszard GrendaNicholas J A WebbStephen D MarksDominique DebrayRichard C L HoltAlain LachauxDeirdre KellyGbenga KazeemNasrullah UndrePublished in: Clinical transplantation (2019)
In pediatric de novo solid organ recipients, the low incidence of BCAR and low efficacy failure rate suggest that PR-T-based immunosuppression is effective and well tolerated to 1-year post-transplantation.